RIGEL PHARMACEUTICALS, INC.

Analyst Reco. Rigel Pharmaceuticals, Inc.

Equities

RIGL

US7665596034

Market Closed - Nasdaq Other stock markets 01:30:00 02/05/2024 am IST			5-day change	1st Jan Change
1.09 ^USD	+3.81%		-3.11%	-24.83%

12/04	Rigel Pharmaceuticals, Inc. Enters into Amendment No. 4 to that Certain Credit and Security Agreement	CI
12/03	Rigel Pharmaceuticals Announces Appointment of Lisa Rojkjaer as Chief Medical Officer	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Citigroup Adjusts Rigel Pharmaceuticals' Price Target to $4 From $3, Maintains Buy Rating	07/03	MT
B. Riley Lifts Rigel Pharmaceuticals' PT to $1.75 From $1.25 After Announced Purchase of US Rights to Gavreto From Blueprint Medicines; Keeps Neutral Rating	26/02	MT
B. Riley Trims Rigel Pharmaceuticals' PT to $1.25 From $1.75, Lowers Peak Sales Estimate for Rezlidhia; Maintains Neutral Rating	09/11	MT
Piper Sandler Assumes Neutral Rating on Rigel Pharmaceuticals With $2 Price Target	03/23/03	MT
Citigroup Adjusts Price Target on Rigel Pharmaceuticals to $3 From $2, Keeps Buy Rating	09/23/09	MT
Health Care Up as Rate Fears Weigh -- Health Care Roundup	03/22/03	DJ
Citigroup Upgrades Rigel Pharmaceuticals to Buy From Neutral, Raises Price Target to $2 From $1.50	02/22/02	MT
HC Wainwright Adjusts Rigel Pharmaceuticals' Price Target to $15 from $7, Keeps Buy Rating	18/22/18	MT
Piper Sandler Adjusts Price Target on Rigel Pharmaceuticals to $2 From $1, Maintains Neutral Rating	17/22/17	MT
Cantor Fitzgerald Raises Rigel Pharmaceuticals Price Target to $2 From $1, Maintains Neutral Rating	03/22/03	MT
BMO Lowers Rigel Pharmaceuticals' Price Target to $3 From $7, Maintains Outperform Rating	09/22/09	MT
B. Riley Lowers Rigel Pharmaceuticals' Price Target to $1.25 from $4 After Disappointing Trial Data on Fostamatinib, Keeps Neutral Rating	09/22/09	MT
Citigroup Downgrades Rigel Pharmaceuticals to Neutral From Buy, Adjusts Price Target to $0.80 From $7	09/22/09	MT
Piper Sandler Cuts Rigel Pharmaceuticals to Neutral From Overweight, Price Target to $1 From $7	09/22/09	MT
Jefferies Lowers Rigel Pharmaceuticals to Hold From Buy, Price Target to $1 From $8	09/22/09	MT
HC Wainwright Adjusts Rigel Pharmaceuticals' Price Target to $7 from $11, Keeps Buy Rating	08/22/08	MT
Cantor Fitzgerald Downgrades Rigel Pharmaceuticals to Neutral from Overweight	08/22/08	MT
B. Riley Initiates Rigel Pharmaceuticals at Neutral with $4 Price Target, Notes Hidden Risks in Phase III Protocol for Warm Autoimmune Hemolytic Anemia	23/22/23	MT
RIGEL PHARMACEUTICALS : JPMorgan Downgrades Rigel Pharmaceuticals to Neutral From Overweight	09/20/09	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Secure and Increase the Performance of your Investments with our Team of Experts at your Side

Securing my Investments

fermer